ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "FDA Approval: Taletrectinib and ROS1 NSCLC"
Episode Synopsis
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of taletrectinib, a next-generation ROS1 kinase inhibitor, for NSCLC with a ROS1 gene fusion. Dr. Enriqueta Felip and Dr. Jorge Nieva join the conversation to help review the data and offer help place this new agent in the proper perspective.
More episodes of the podcast Lung Cancer Considered
LCC in Greek: WCLC 2025 Highlights
10/10/2025
LCC in Arabic: WCLC 2025 Highlights
03/10/2025
Lung Cancer Considered: Targeting EGFR NSCLC
03/10/2025
LCC in Korean: WCLC 2025 Highlights
30/09/2025
LCC in Portuguese: WCLC 2025 Highlights
16/09/2025
In God we trust